Pan-cancer analyses demonstrated that FOXM1 expression is increased in TCGA tumors with p53 mutations and Rb loss of function, and we validated these findings using genetic modeling of p53, Rb/E2F1, and Cyclin E1 in FTE cells. This evidence concerns the gene E2F1 and cancer.